What is the recommendation for patients >75 years of age with ASCVD?
The recommendation is to consider continuation of high-intensity therapy in patients >75 years of age with ASCVD if they are tolerating the statin and have a low risk of competing morbidities. It may also be reasonable to add ezetimibe to moderate-intensity therapy in patients with ASCVD for whom high-intensity therapy is indicated but cannot be used, provided their LDL-C level remains 70 mg/dL ( 1.8 mmol/L) on moderate-intensity therapy. The same reasoning holds for any patient whose LDL-C level remains 70 mg/dL ( 1.8 mmol/L) on maximally tolerated statin therapy.